The impact of ABO incompatibility between donor and recipient on engraftment and transfusion requirement was studied in 95 adults who underwent unrelated cord blood transplantation (CBT). The patients included 27 ABOidentical, 29 minor, 21 major and 18 bidirectional ABOincompatible recipients. Neutrophil engraftment did not differ between ABO-identical/minor ABO-incompatible and major/bidirectional ABO-incompatible recipients (hazard ratio (HR) 1.17, P ¼ 0.48). Cumulative incidence of platelet engraftment in ABO-identical/minor ABOincompatible recipients was higher than in major/bidirectional ABO-incompatible recipients (HR 1.88, P ¼ 0.013). In addition, fewer platelet transfusions were required during the first 60 days after CBT in ABO-identical/ minor ABO-incompatible recipients (HR 0.80, P ¼ 0.040). RBC engraftment did not differ between the two groups (HR 1.25, P ¼ 0.33). However, fewer RBC transfusions were required in ABO-identical/minor ABO-incompatible recipients than in major/bidirectional ABO-incompatible recipients (HR 0.74, Po0.005). No patients developed pure red-cell aplasia after CBT. These results indicate that ABO incompatibility affected platelet engraftment and transfusion requirement of RBC and platelet in CBT recipients. Further studies including larger patient numbers are required to elucidate the impact of ABO incompatibility on the clinical outcome of CBT.
Introduction
The presence of ABO incompatibility between donor and recipient is common in allogeneic hematopoietic SCT. The incompatibility is defined as 'major' when the recipient plasma has isohemagglutinins against donor RBC antigens, and 'minor' when the donor has isohemagglutinins against recipient RBC antigens. When combined features of major and minor incompatibility coexist, the incompatibility is defined as 'bidirectional'. Most previous studies showed no significant effect of major/bidirectional ABO incompatibility on the incidence of graft failure, GVHD, or survival after SCT. 1, 2 However, many reports have described the occurrence of pure red-cell aplasia (PRCA) or delayed erythroid engraftment and increased requirement for RBC transfusion in patients after major/bidirectional ABO-incompatible allogeneic bone marrow transplantation or PBSCT. [3] [4] [5] In the present study, we investigated the impact of major/bidirectional ABO incompatibility on engraftment and transfusion requirements in adult patients who had undergone the unrelated cord blood transplantation (CBT) at a single institute.
Patients and methods

Patients
Between August 1998 and November 2005, 95 consecutive adult patients underwent unrelated CBT following a conditioning regimen including 12 Gy total body irradiation at The Institute of Medical Science, The University of Tokyo (Table 1 ). The study patients included 27 ABO-identical, 29 minor, 21 major and 18 bidirectional ABO-incompatible recipients of CBT. Transplantation procedures and supportive care have been described previously. 6 No patients received a conditioning regimen including antithymocyte globulin (ATG). Cyclosporine (CSP, 3 mg/kg/day) with a short course of methotrexate was administered intravenously to prevent acute GVHD in 92 patients, and CSP was given alone to the remaining three patients. To facilitate neutrophil engraftment, recombinant human G-CSF was administered intravenously at a dose of 5 mg/kg/day from day þ 1 after CBT. Anti-CMV high-titer intravenous immunoglobulin at a dose of 10 g was administered twice a month from day À2 until day þ 100 or longer after CBT.
Transfusion guidelines
Patients were transfused with packed RBCs to maintain a hemoglobin concentration of greater than 8 g/dl, and with packed platelets to maintain a platelet count of greater than 20 Â 10 9 /l. All platelet concentrates were prepared by single-donor apheresis. In general, a pack containing 2.0 Â 10 11 platelets (10 U) or more was used. All packed RBCs were derived from 400 ml blood (2 U). All packed RBCs and platelets transfused were leukocyte-filtered and irradiated to 25 Gy. The ABO type of RBCs and platelets transfused after CBT was determined by the blood groups of donor and recipient as described previously. 7, 8 In minor ABO-incompatible recipients, donor-type RBCs and recipient-type platelets were transfused. In major ABO-incompatible recipients, recipient-type RBCs and donor-type platelets were transfused. In bidirectional ABO-incompatible recipients, group-O RBCs and group-AB platelets were transfused. For RBC transfusion in ABO-incompatible CBT, plasma-containing antibody to recipient ABO antigens was removed by washing and centrifugation.
Definitions
Neutrophil engraftment was defined as the day of achieving an ANC greater than 0.5 Â 10 9 /l. for 3 consecutive days. Platelet engraftment was defined as the day of achieving a platelet count greater than 20 Â 10 9 /l for 3 consecutive days without transfusion. RBC engraftment was defined as the day of achieving a reticulocyte count greater than 1% for 3 consecutive days.
High-risk diseases were defined as acute leukemia and lymphoma in more than the first complete remission, Philadelphia chromosome-positive acute lymphoblastic leukemia in any phases, myelodysplastic syndromes in advanced phase, and chronic myelogenous leukemia in more than the first chronic phase. Low-risk diseases were defined as other than the above. HLA-A and -B matching was confirmed by low-resolution typing methods and HLA-DRB1 matching was confirmed by high-resolution typing methods.
Statistical analysis
The cumulative incidence of engraftment was estimated in a competing risks setting, death and relapse being treated as competing risks. 9 . In multivariate analysis, a Cox proportional hazards model was used to assess the independent effect of risk factors on engraftment and transfusion requirement after CBT. We used the stepwise variable selection procedures with a significance level of 5%. Other than ABO incompatibility, the following factors were studied: age (less than 40 years versus 40 years or more), gender (male versus female), disease status (low-risk versus high-risk), pretransplant CMV serostatus (negative versus positive), total nucleated cell (TNC) dose (less than 2.5 Â 
Results
Neutrophil engraftment
Of 95 patients who underwent CBT, three developed autologous hematopoietic recovery after CBT, and other four patients died before neutrophil recovery. Successful neutrophil engraftment was achieved in the remaining Figure 1a , Table 2 ). The median days to neutrophil engraftment were 22, 23, 22 and 22, respectively. The cumulative incidence of neutrophil engraftment in ABO-identical/minor ABOincompatible CBT did not differ significantly from that in major/bidirectional ABO-incompatible CBT (median day, 22 versus 22; cumulative incidence, 95 versus 90%; hazard ratio (HR) 1.17; P ¼ 0.48) (Figure 1b , Table 3 ). The smaller CD34-positive cell dose was significantly associated with delayed neutrophil engraftment after CBT (HR 0.65, P ¼ 0.049) ( Table 3) . Instead of an ANC of 0.5 Â 10 9 /l, when the days of achieving an ANC greater than 1.0 Â 10 9 /l for 3 consecutive days were compared, the cumulative incidence in ABO-identical/minor ABO-incompatible CBT also did not differ significantly from that in major/ bidirectional ABO-incompatible CBT (median day, 25 versus 24; cumulative incidence, 95 versus 90%; HR 1.15; P ¼ 0.52).
Platelet engraftment and transfusion
Of the 88 patients with neutrophil engraftment, three patients relapsed and two patients died without relapse, before platelet engraftment. Platelet engraftment was achieved in the remaining 83 patients at a median of 40 (range: 22-99) days after CBT. In patients with ABOidentical, minor, major and bidirectional ABO-incompatible CBT, the cumulative incidences of platelet engraftment at 90 days after CBT were 89, 90, 86 and 61%, respectively ( Figure 2a , Table 2 ). The median days of platelet engraftment were 39, 41, 42 and 59, respectively. The cumulative incidence of platelet engraftment in ABO-identical/minor ABO-incompatible CBT was significantly higher than that in major/bidirectional ABOincompatible CBT (median day, 40 versus 42; cumulative incidence, 91 versus 74%; HR 1.88; P ¼ 0.013) (Figure 2a , Table 3 ). Pretransplant CMV seropositivity and the smaller CD34-positive cell dose were also isolated risk factors for delayed platelet engraftment after CBT (HR 0.38, Po0.005, and HR 0.58, P ¼ 0.021, respectively) ( Table 3) . Instead of a platelet count of 20 Â 10 9 /l, when the days of achieving a platelet count greater than 50 Â 10 9 /l for 3 consecutive days without requiring a transfusion were compared, the cumulative incidence in ABO-identical/ minor ABO-incompatible CBT did not differ significantly from that in major/bidirectional ABO-incompatible CBT (median day, 48 versus 48; cumulative incidence, 87 versus 68%; HR 1.27; P ¼ 0.31).
Of the 88 patients with neutrophil engraftment, two relapsed and another died without relapse within 60 days after CBT. Two patients who developed massive bleeding died within 60 days after CBT, and were therefore not included in further analysis. In the remaining 85 patients, the requirement for platelet transfusion was compared after adjusting for patient body weight. In patients with ABO-identical, minor, major and bidirectional ABO-incompatible CBT, the average units of platelets transfused during the first 60 days after CBT were 9.4, 7.6, 11.0 and 9.8 U/kg, respectively ( Table 2 ). The requirement for platelet transfusion in ABO-identical/ minor ABO-incompatible recipients was significantly lower than in major/bidirectional ABO-incompatible recipients (average, 8.5 versus 10.5 U/kg; HR 0.80; P ¼ 0.040) ( Table 4) .
RBC engraftment and transfusion
Of the 88 patients with neutrophil engraftment, one patient relapsed and another died without relapse before RBC engraftment. In the remaining 86 patients, RBC engraftment was achieved at a median of 33 (range: 21-96) days after CBT. In patients with ABO-identical, minor, major and bidirectional ABO-incompatible CBT, the cumulative incidences of RBC engraftment at 90 days after CBT were 89, 90, 90 and 72%, respectively ( Figure 3a , Table 2 ). The median days of RBC engraftment were 35, 32, 35 and 33, respectively. The cumulative incidence of RBC engraftment in ABO-identical/minor ABO-incompatible CBT did not differ significantly from that in major/bidirectional ABO-incompatible CBT (median day, 33 versus 33; cumulative incidence, 91 versus 85%; HR 1.25; P ¼ 0.33) (Figure 3b , Table 3 ). Pretransplant CMV seropositivity and the smaller CD34-positive cell dose were also isolated risk factors for delayed RBC engraftment after CBT (HR 0.47, P ¼ 0.017 and HR 0.61, P ¼ 0.030, respectively) ( Table 3) .
The requirement of RBC transfusion was then studied in 85 patients who did not develop massive bleeding and survived more than 60 days after CBT. In patients with ABO-identical, minor, major and bidirectional ABOincompatible CBT, the average units of RBCs transfused during the first 60 days after CBT were 0.54, 0.40, 0.64 and 0.61 U/kg, respectively ( Table 2 ). The requirement for RBC transfusion in ABO-identical/minor ABO-incompatible CBT was significantly lower than that in major/bidirectional ABO-incompatible CBT (average, 0.47 versus 0.63 U/kg, HR 0.74, Po0.005) ( Table 3) . Pretransplant CMV seropositivity was also an isolated risk factor for increased RBC transfusion after CBT (HR 1.49, P ¼ 0.013) ( Table 4) .
In seven patients, more than 50 days were required for RBC engraftment after CBT. These patients included one ABO-identical, two minor, three major and one bidirectional ABO-incompatible recipient. All seven patients had not achieved platelet engraftment on the day of RBC engraftment. In six of the seven patients, neutrophil engraftment was also delayed to more than 30 days after CBT. Therefore, no patients were considered as having developed PRCA after CBT. In addition, no patients developed delayed massive immune hemolysis after CBT. 
Discussion
In the present study, we investigated the impact of ABO incompatibility on engraftment and transfusion requirement after CBT. Platelet engraftment was significantly delayed in major/bidirectional ABO-incompatible CBT, with a significantly increased requirement for platelet transfusion. In addition, although RBC engraftment in major/bidirectional ABO-incompatible CBT was not significantly delayed, the requirement of RBC transfusion was more significantly increased than with ABO-identical/ minor ABO-incompatible CBT. However, no patients developed PRCA after CBT. Many previous studies have reported the occurrence of PRCA or delayed RBC engraftment and the increased requirement of RBC transfusion in patients with major/ bidirectional ABO-incompatible SCT.
1,2 This phenomenon is due to the presence of recipient isoagglutinins directed at ABH antigens on donor-derived erythroid precursor cells. 3, 10 Isoagglutinins are also infused with the administration of anti-CMV high-titer immunoglobulin. In our study of patients receiving ABO-identical grafts, the requirement for RBC transfusion in blood group-O recipients was not significantly different from that in blood group-A recipients (P ¼ 0.79), suggesting that the influence of isoagglutinins infused with anti-CMV high-titer immunoglobulin products on transfusion requirement might be minimal. The incidence of PRCA in patients with major/ bidirectional ABO-incompatible SCT may vary depending on stem cell source (bone marrow cells or G-CSF-mobilized peripheral blood stem cells), conditioning regimen (myeloablative or nonmyeloablative) and type of GVHD prophylaxis (cyclosporine, with or without methotrexate or T-cell depletion). 1, 11 For prolonged PRCA after SCT, the efficacy of various therapies such as erythropoietin, 12 ATG, 13 donor lymphocyte infusion 14 and anti-CD20 monoclonal antibody 15 was reported. However, our CBT recipients with a myeloablative conditioning regimen did not develop PRCA or require such specific therapies.
Our results showed that platelet engraftment was significantly delayed in major/bidirectional ABO-incompatible CBT, with a significantly increased requirement of platelet transfusion. Badros et al. 16 also showed that major/ bidirectional ABO incompatibility led to delayed platelet engraftment and an increased requirement for platelet transfusion in patients who underwent PBSCT using a nonmyeloablative conditioning regimen. Although ABH antigens are also expressed on platelets, 17, 18 most of the previous studies did not show an association between major/bidirectional ABO incompatibility and delayed platelet engraftment or increased platelet transfusion requirement after SCT. The reason for the delayed platelet engraftment in major/bidirectional ABO-incompatible CBT could not be clearly explained.
Most previous studies have shown no significant effect of major/bidirectional ABO incompatibility on survival after SCT. However, some investigators have shown that recipients of bidirectional ABO-incompatible SCT had a lower survival rate. 19, 20 In the present study, because all patients with bidirectional ABO-incompatible CBT had high-risk diseases (Table 1) , we could not obtain a clear result regarding an association between bidirectional ABO incompatibility and survival after CBT (data not shown). Further studies including larger patient numbers are required to elucidate the impact of ABO incompatibility on clinical outcome of CBT. 
